www.fdanews.com/articles/86996-cell-genesys-reports-on-trial-of-cg0070-update
CELL GENESYS REPORTS ON TRIAL OF CG0070 -- UPDATE
May 22, 2006
Cell Genesys has announced preliminary results of a Phase I clinical trial of CG0070 in patients with recurrent bladder cancer who have failed previous therapy with bacillus Calmette-Guerin, the current standard therapy for recurrent bladder cancer.
Nine patients have been treated with escalating single-dose administrations of CG0070. Evidence of antitumor activity documented by a complete response at follow-up cystoscopy was obtained in three of the nine patients treated. Treatment was tolerable with no serious adverse events or dose limiting toxicities reported to date.